SCHEMBL28285348

SCHEMBL28285348

C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncc2cc[nH]c2n1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK3 P52333 20/20 0.68
JAK2 O60674 16/20 0.68
JAK1 P23458 11/20 0.68
TYK2 P29597 6/20 0.68
PKN2 Q16513 5/20 0.68
ROCK1 Q13464 4/20 0.68
LRRK2 Q5S007 4/20 0.68
ROCK2 O75116 3/20 0.68
PRKCD Q05655 3/20 0.68
STK3 Q13188 3/20 0.68
CAMK2D Q13557 3/20 0.68
LCK P06239 3/20 0.68
RET P07949 3/20 0.68
CAMK1D Q8IU85 3/20 0.68
MARK3 P27448 2/20 0.68
MARK2 Q7KZI7 2/20 0.68
DCLK1 O15075 2/20 0.68
ABL1 P00519 2/20 0.68
FYN P06241 2/20 0.68
DMPK Q09013 2/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24200717 0.83 JAK3 (0.75) JAK3JAK2JAK1TYK2PKN2
SCHEMBL30911326 0.83 JAK3 (0.75) JAK3JAK2JAK1TYK2PKN2
SCHEMBL22418507 0.83 JAK3 (0.75) JAK3JAK2JAK1TYK2PKN2
Tofacitinib SCHEMBL30925309 0.81 JAK3 (1.00) JAK3JAK2JAK1TYK2PKN2
SCHEMBL10062081 0.81 JAK3 (0.75) JAK3JAK2JAK1TYK2PKN2
Tasocitinib SCHEMBL30341861 0.81 JAK3 (1.00) JAK3JAK2JAK1TYK2PKN2
Tofacitinib SCHEMBL322753 0.81 JAK3 (1.00) JAK3JAK2JAK1TYK2PKN2
Tofacitinib SCHEMBL23199919 0.81 JAK3 (1.00) JAK3JAK2JAK1TYK2PKN2
Tasocitinib SCHEMBL23058868 0.81 JAK3 (1.00) JAK3JAK2JAK1TYK2PKN2
SCHEMBL353500 0.81 JAK3 (0.75) JAK3JAK2JAK1TYK2PKN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109608468-B Tofacitinib citrate impurity, and synthesis method and application thereof 成都倍特药业股份有限公司 2020-09-29 CN claimed
CN-109608468-A Tofacitinib citrate impurity, and synthesis method and application thereof 成都倍特药业有限公司 2019-04-12 CN claimed
CN-109608468-B Tofacitinib citrate impurity, and synthesis method and application thereof 成都倍特药业股份有限公司 2020-09-29 CN disclosed
CN-109608468-B Tofacitinib citrate impurity, and synthesis method and application thereof 成都倍特药业股份有限公司 2020-09-29 CN disclosed
CN-109608468-A Tofacitinib citrate impurity, and synthesis method and application thereof 成都倍特药业有限公司 2019-04-12 CN disclosed
CN-109608468-A Tofacitinib citrate impurity, and synthesis method and application thereof 成都倍特药业有限公司 2019-04-12 CN disclosed